Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

This is ASCO week. Revolution Medicines' plenary session on Saturday is the event the entire oncology community has been building toward since the Phase 3 topline readout on April 13. We know the headline numbers: 13.2 months median OS versus 6.7 months (HR 0.40, p<0.0001) in second-line pancreatic cancer. What we do not know: PFS data, detailed subgroup analyses, mature survival curves, safety details, and the full tumor response assessment. These are the data points that will determine whether daraxonrasib receives a broad or narrow label, how quickly it is adopted in clinical practice, and whether the commercial opportunity is at the low or high end of the $2B to $4B peak sales range. Truist projects an approval by end of Q3 under the CNPV program. If Revolution files shortly after or concurrent with ASCO, the 50-day Foundayo precedent could produce an approval by August or September. Beyond Revolution, ASCO will feature hundreds of abstracts across oncology, with ADC data, checkpoint inhibitor combinations, and cell therapy updates drawing the most commercial interest. The ADC modality in particular is on a run: Datroway was approved for first-line TNBC on May 22, just two weeks after Enhertu's early breast cancer label expansion. The label expansions are coming faster than at any point in ADC history. 👉 Read Full Analysis

🔮 What To Watch

🔬 Clinical & Research Updates

Datroway Approved for First-Line Triple-Negative Breast Cancer AZN | DSNKY

The FDA approved AstraZeneca/Daiichi Sankyo's Datroway (datopotamab deruxtecan) on May 22 as a first-line treatment for patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor therapy. Datroway is a Trop-2-directed ADC. This is the second new ADC to receive a label expansion or approval in the early/first-line setting in two weeks, following Enhertu's early breast cancer approval on May 16. The TNBC market has historically been among the hardest to treat, with limited targeted therapy options for patients who cannot receive immunotherapy. Datroway fills a critical gap.

Gilead Hepcludex Approved as First-Ever HDV Treatment in the U.S. GILD

The FDA granted accelerated approval for Gilead's Hepcludex (bulevirtide) on May 23 for adults with chronic hepatitis delta virus (HDV) infection, making it the first and only approved treatment for HDV in the United States. HDV is the most severe form of viral hepatitis, affecting an estimated 12 million to 72 million people globally. GILD shares rose 3% on the news. The approval adds another franchise to Gilead's hepatitis/HIV portfolio and complements its ongoing ADC and cell therapy diversification.

🌍 Policy & Regulatory

EU Locks In Critical Medicines Act

The European Parliament and EU member states reached a provisional agreement on the Critical Medicines Act (CMA) on May 22, according to The Pharma Letter. The CMA is designed to strengthen medicine supply chains, reduce dependency on non-EU API and raw material sources, and establish strategic reserves of critical medicines. The legislation comes as the Iran war continues to disrupt pharmaceutical trade routes and global API supply chains. Separately, EFPIA warned that the U.S. Most Favored Nation pricing policy could widen disparities in access to new medicines across Europe as drugmakers reassess launch and investment strategies.

📋 The Week in Review

📅 The Week Ahead

👉 Read Full Analysis

We know the headline: 13.2 months OS vs. 6.7 months, HR 0.40. What we need from the plenary:

PFS data: Not yet disclosed. A strong PFS result (HR <0.50) would confirm that daraxonrasib delays progression and extends survival, strengthening the approval case and the commercial positioning.

Subgroup analyses: Does daraxonrasib work equally well across RAS mutation subtypes (G12D, G12V, G12C, others)? Does it work in patients with prior immunotherapy? Does age, performance status, or geographic region affect outcomes? A broadly positive subgroup analysis supports a wide label.

Mature survival curves: The topline data came from the first interim analysis. Mature curves will show whether the survival benefit is sustained or converges over time. A sustained separation of the curves is the strongest possible result.

Safety details: We know the drug was "generally well tolerated." The plenary will provide detailed adverse event rates, dose modifications, treatment discontinuations, and quality of life data. Clean safety supports both approval and commercial adoption.

Presenter commentary: Brian Wolpin (Dana-Farber) is one of the most respected pancreatic cancer investigators in the world. His framing of the data, particularly around clinical significance and practice-changing potential, will shape how oncologists interpret the results.

💊 ADC Label Expansion Tracker: 2026

Two ADC label expansions in the first-line or curative setting in two weeks. Both from the AstraZeneca/Daiichi Sankyo partnership. Both targeting breast cancer subtypes. This is the ADC modality moving from late-line salvage therapy to frontline standard of care, the same trajectory that checkpoint inhibitors followed from 2015 to 2020.

For Daiichi Sankyo's $14.6B oncology revenue target by 2030, these label expansions are essential. Each expansion adds a larger patient population (early-stage and first-line patients outnumber late-line patients by multiples).

📊 Capital Markets: ASCO Week Positioning

ASCO typically drives significant stock movement for companies presenting pivotal data. Revolution Medicines (RVMD) is the most obvious mover. The stock has already risen from $96 pre-Phase 3 data (April 12) to approximately $149 post-data/$2B raise (mid-April). The plenary presentation could drive another leg up if the detailed data confirm the topline, or pull back if PFS or subgroups disappoint.

Other stocks to watch during ASCO: Merck (Keytruda franchise updates), BMS (checkpoint combinations), Gilead (Trodelvy data in new tumor types), AstraZeneca/Daiichi Sankyo (ADC pipeline updates), and smaller biotechs presenting Phase 2 data that could trigger M&A interest.

🎯 Catalyst Calendar: ASCO Week and Beyond

👉 Visit The Pro Hub

Limited ASCO-week sponsorship slots available (May 29 - June 2). Reach 65,000+ professionals during the biggest oncology event of the year. Learn more →

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →